References
- 1. GYURKOCZA B., REZVANI A., STORB RF. Allogeneic hematopoietic cell transplantation: the state-of-the-art. Expert Rev Hematol. 2010; 3(3):285-99.
- 2. BARON F., STORB R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review.
- Springer Semin Immunopathol. 2004; 26(1-2):71-94.
- 3. BARONF., STORB R., LITTLE MT. Hematopoietic cell transplantation: five decades of progress. Arch Med Res. 2003; 34(6):528-44.
- 4. STAAL F.J., BAUM C., COWAN C., DZIERZAK E., HACEIN-BEY-ABINA S., KARLSSON S., et al. Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications. Leukemia. 2011; 25(7):1095-102.
- 5. SAULNIER N., DI CAMPLI C., ZOCCO M.A., DI GIOCCHINNO G., NOVI M., GASPARRINI A. From stem cell to solid organ. Bone marrow, peripheral blood or umbilical cord blood as favorable source? Eur Rev Med Pharmacol Sci. 2005; 9(6):315-24.
- 6. CANELLOS G.P., ANDERSSON J.R., PROPERT K.J., NISSE N., COOPER M.R., HENDERSSON E.S., et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21):1478-84.
- 7. DIEHL V., FRANKLIN J., PFEUNDSCHUCH M., LATHAN B., PAULUS U., HASENCLEVER D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003; 348(24):2386-95.
- 8. SANTORO A., MAGAGNOLI M., SPINA M., PINOTTI G., SIRACUSANO L., MICHIELI M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007; 92(1):35-41.
- 9. JOSTING A., RUDOLPH C., MAPARA M., GLOSSMANN J.P., SIENIAWSKI M., SIEBER M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005; 16(1):116-23.
- 10. GLOSSMANN J.P., STAAK J.O., NOGOVA L., DIEHL V., SCHEID C., KISRO J., et al. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol. 2005; 84(8):517-25.
- 11. JOSTING A., NOGOVA L., FRANKLIN J., GLOSSMANN J.P., EICH H.T., SIEBER M., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J ClinOncol. 2005; 23(7):1522-9.
- 12. SELBY P., PATEL P., MILAN S., MELDRUM M., MANSI J., MBIDDE E., et al. ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer. 1990; 62(2):279-85.
- 13. POWLES R.L., MORGENSTERN G.R., KAY H.E., MCELWAIN T.J., CLINK H.M., DADY P.J.. et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983; 1(8325):612-5.
- 14. BEATTY P.G., CLIFT R.A., MICKELSON E.M., NISPEROS B.B., FLOURNOY N., MARTIN P.J., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985; 313(13):765-71.
- 15. BRUNSTEIN C.G.,FUCHS E.J., CARTER S.L., KARANES C., COSTA L.J., WU J., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2):282-8.
- 16. AL MALKI M.M., HOROWITZ M., HANDGRETINGER R., LEUNG W., ROY D.C., HUANG X.J., et al. Proceedings from the Second Haploidentical Stem-cell Transplantation Symposium - Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016; S1083-8791(16)00004-5.
- 17. KANATE A.S., MUSSETTI A., KHARFAN-DABAJA M.A., AHN K.W., DI GILIO A., BEITINJANEH A., et al. Reducedintensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood. 2016; in press.
- 18. BAYRAKTAR U.D., MILTON D.R., GUINDANI M., RONDON G., CHEN J., AL-ATRASH G., et al. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2015; S1083-8791(15)00709-0.
- 19. BRAMMER J.E., KHOURI I., GABALLA S., ANDERLINI P., TOMULEASA C., AHMED S., et al. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2015: S1083-8791(15)00685-0.
- 20. O’DONNEL P.V., LUZNIK L., JONES R.J., VOGELSANG G.B., LEFFEL M.S., PHELPS M., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.Biol Blood Marrow Transplant. 2002; 8(7):377-86.
- 21. BASHEY A., ZHANG X., SIZEMORE C.A., MANION K., BROWN S., HOLLAND H.K., et al. T-cell-replete HLAhaploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-6.
- 22. DI STASI A., MILTON D.R., POON L.M., HAMDI A., RONDON G., CHEN J., et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigenmatched unrelated and related donors. Biol Blood Marrow Transplant. 2014; 20(12):1975-81.